Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells

Tyrosine kinase inhibitors ( TKI ), including imatinib ( IM ), improve the outcome of CML therapy. However, TKI treatment is long‐term and can induce resistance to TKI , which often leads to a poor clinical outcome in CML patients. Here, we examined the effect of continuous IM exposure on intracellular energy metabolism in K562 cells, a human Philadelphia chromosome‐positive CML cell line, and its subsequent sensitivity to anti‐cancer agents....